Business Wire Feed
Palleon Pharmaceuticals Presents First-in-Class B7-H3 Targeted Sialidase at the 2026 AACR Annual Meeting
E-688/HLX316 activates both innate and adaptive anti-tumor immunity through tumor-targeted enzymatic desialylation Initiation of a first-in-human clinical trial of E-688/HLX316 is underway in China, following IND approval granted to strategic collaborator Henlius by the National more...
Maxell Establishes Corporate Byline “Micro batteries. Maximum impact.”
Clarifying the Value Maxell Provides as a BtoB Company and Reestablishing its Corporate Image GloballyTOKYO--(BUSINESS WIRE)--#Branding--Maxell, Ltd. (TOKYO: 6810) has established the new corporate byline “Micro batteries. Maximum impact.” with the aim of evolving its more...
Samsung Bioepis Presents Nonclinical Data for its First Novel Antibody-Drug Conjugate Candidate SBE303 at AACR 2026
- Nonclinical findings from pharmacology, pharmacokinetics, and toxicology studies support the advancement of SBE303 into clinical development with a favorable therapeutic index (TI), with its first-in-human Phase I clinical trial began in March this year more...
Claritev Corporation Announces First Quarter 2026 Earnings Conference Call
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its more...
CenterWell Introduces the Fulfillment Index, a New Measure of What It Means to Age Well
The CenterWell Fulfillment Index offers a new way to understand what drives wellbeing as people ageLOUISVILLE, Ky.--(BUSINESS WIRE)--CenterWell, the health care services business of Humana Inc. (NYSE: HUM), today introduced the CenterWell Fulfillment Index, a more...
TTP Group Announces the Sale of LEX Diagnostics
CAMBRIDGE, England--(BUSINESS WIRE)--TTP today announced the acquisition by QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based molecular diagnostics company and a spin-out of TTP Group. Founded more...
Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy
Aicuris’s three antiviral assets complement Asahi Kasei’s therapy portfolio Aicuris revenue expected to reach $500 million by 2030 FDA has granted Priority Review for the pritelivir New Drug Application. Prescription Drug User Fee Act (PDUFA) more...
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting more...
HSS Studies Contribute Early Evidence to Help Guide Emerging Perioperative Considerations for Patients Using GLP‑1 Medications
PHOENIX--(BUSINESS WIRE)--At this year’s American Society of Regional Anesthesia and Pain Medicine (ASRA) annual meeting, researchers at Hospital for Special Surgery (HSS) presented two studies focused on glucagon-like peptide-1 (GLP-1) agonist usage in patients undergoing more...
Inocras and Broad Institute Researchers Present New TCGA Whole-Genome Cancer Insights, Accelerating Discovery in Cancer Genomics
Insights derived from one of the largest datasets with over 250 million harmonized variant calls from over 8,000 tumor-normal whole genomes from more than 30 different cancer types will be presented at the AACR Annual more...
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. more...
HSS Presents New Research Leveraging AI to Uncover Insights Related to Pain Risk and Anesthesia Education at ASRA Annual Meeting
PHOENIX--(BUSINESS WIRE)--At this year’s American Society of Regional Anesthesia and Acute Pain Medicine (ASRA) annual meeting, investigators at Hospital for Special Surgery (HSS) presented significant studies leveraging artificial intelligence (AI) to provide insights into long-term more...
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
-Efficacy and safety data shared at IMMUNOLOGY2026 reinforce potential of ZL-1503 as a first-in-class treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Strong inhibition of both inflammatory and pruritic pathways over 112 more...
Boston Health AI Secures Its US Footprint Through Implementation with Avicenna Clinics
HOUSTON--(BUSINESS WIRE)--#AIinHealthcare--Boston Health AI, a healthcare AI company focused on conversational clinical intelligence, today announced the successful launch of its clinical AI platform at Avicenna Clinics following three months of live deployment and expansion across more...
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products. In their order, FDA concluded that: “Scientific studies have shown more...
My Mountain Mover Expands into Dental with Virtual Assistants Built for Practice Operations
ORANGE, Calif.--(BUSINESS WIRE)--#dentalvirtualassistant--My Mountain Mover, the leading provider of Medical Virtual Assistants for healthcare practices across the United States, proudly announces its official expansion into the dental industry, designed to meet the unique demands of more...
Blue Cross Blue Shield of Michigan Postpones Modifier 25 Policy in Response to Osteopathic Advocacy
Four leading osteopathic organizations joined the AOA to secure the policy delayCHICAGO--(BUSINESS WIRE)--The postponement of Blue Cross Blue Shield of Michigan’s (BCBSM) proposed reimbursement policy affecting evaluation and management (E/M) services billed with modifier 25 more...
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal cancer shows disease control rate (DCR) of 77% in patients and long-term survival beyond 20 months in a subset of heavily pretreated patients more...
Cross Country Healthcare to Hold First Quarter 2026 Earnings Conference Call on Thursday, May 7, 2026
BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (Nasdaq: CCRN) will hold its quarterly conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026 at 5:00 P.M. Eastern Time. Cross Country more...
GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after U.S. markets more...
hc1® CEO, Bradley Bostic Recognized as a 2026 Notable Leader in Health Care for Driving AI-Powered Health System Transformation
INDIANAPOLIS--(BUSINESS WIRE)--hc1®, the leader in agentic lab data intelligence for healthcare, today announced that its Founder, Chairman, and CEO, Bradley Bostic, has been named to the prestigious Crain's Chicago Business Notable Leaders in Health Care more...
SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026
Ultrasensitive, structural variant-based ctDNA monitoring reliably tracks therapeutic response and predicts progression in metastatic breast cancer, and is a strong independent prognostic marker in advanced ovarian cancersMORRISVILLE, N.C.--(BUSINESS WIRE)--#AACR--SAGA Diagnostics, a pioneer in blood-based cancer more...
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases; at 1.6 mg/kg dose, the confirmed iORR was 62.5% more...
intoDNA Presents Data on Two Novel Assays, sSTRIDE-NER and sSTRIDE-PARP1, in Poster Presentations at the 2026 AACR Annual Meeting
sSTRIDE-NER offers new opportunities to functionally profile NER capacity in cancer cell models and patient-derived samples sSTRIDE-PARP1 enables direct, functional measurement of PARP1 trapping at single-strand DNA breaks in situKRAKÓW, Poland--(BUSINESS WIRE)--intoDNA, a global precision more...
Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026
Data highlight biomarker-linked activity and in vivo efficacy of STX-6398, supporting small-molecule CKAP2 modulation as a novel therapeutic approach in cancerSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#AACR26--Soley Therapeutics, a biotechnology company advancing novel therapeutics informed by integrated more...